Abstract

The Emory VTEU has proven essential in the fight against the pandemic. This supplement will allow for further investigations into Treatments trials (20-0006) and Vaccines trials (20-0003 and Moderna Phase III) against COVID-19. 1

Public Health Relevance

The Emory VTEU will participate in CoVPN 3001 to demonstrate the efficacy of mRNA-1273 to prevent COVID-19 and evaluate the safety and reactogenicity of 2 injections of the mRNA-1273 vaccine given 28 days apart. 1

  Funding Agency

Agency
National Institute of Health (NIH)
Institute
National Institute of Allergy and Infectious Diseases (NIAID)
Type
Research Project with Complex Structure Cooperative Agreement (UM1)
Project #
3UM1AI148576-01S2
Application #
10199576
Study Section
Program Officer
Gill, Ranjodh Sunny
Project Start
2020-07-13
Project End
2022-11-30
Budget Start
2020-07-13
Budget End
2020-11-30
Support Year
1
Fiscal Year
2020
Total Cost
Indirect Cost

  Institution

Name
Emory University
Department
Internal Medicine/Medicine
Type
Schools of Medicine
DUNS #
066469933
City
Atlanta
State
GA
Country
United States
Zip Code
30322